Stocks · News reference
Entera Bio Ltd. has announced the appointment of Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-27 AccNo: 0001178913-26-004854 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)These
U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.